Both STIM1 and ORAI1 were found to be overexpressed in both prostate cancer cell lines, while in PBMCs the expression of STIM1 and ORAI1 was very low or absent, implying that both biomarkers are specific for tumor cells in the bloodstream. Here, ORAI1 is linked to prostate carcinoma.